WO2000023472A3 - Interferon-beta fusion proteins and uses - Google Patents
Interferon-beta fusion proteins and uses Download PDFInfo
- Publication number
- WO2000023472A3 WO2000023472A3 PCT/US1999/024200 US9924200W WO0023472A3 WO 2000023472 A3 WO2000023472 A3 WO 2000023472A3 US 9924200 W US9924200 W US 9924200W WO 0023472 A3 WO0023472 A3 WO 0023472A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- beta
- fusion proteins
- beta fusion
- polypeptide
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 3
- 108090000467 Interferon-beta Proteins 0.000 title abstract 3
- 229960001388 interferon-beta Drugs 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108010005716 Interferon beta-1a Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 229960004461 interferon beta-1a Drugs 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14235099A IL142350A0 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and pharmaceutical compositions containing the same |
AU13158/00A AU766190B2 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
JP2000577197A JP4761621B2 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
EA200100447A EA005005B1 (en) | 1998-10-16 | 1999-10-15 | HUMAN INTERFERON beta-1alpha HYBRID POLYPEPTIDE, MUTANTS THEREOF AND DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF |
NZ510559A NZ510559A (en) | 1998-10-16 | 1999-10-15 | Glycosylated interferon-beta fusion proteins that are as active as forms that are not fusion proteins |
SI9930919T SI1121382T1 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
DE69931507T DE69931507T2 (en) | 1998-10-16 | 1999-10-15 | INTERFERON-BETA FUSION PROTEINS AND ITS USES |
MXPA01003790A MXPA01003790A (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses. |
EEP200100223A EE05111B1 (en) | 1998-10-16 | 1999-10-15 | Interferon beta-fusion proteins and their use |
EP99956574A EP1121382B9 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
BR9915548-6A BR9915548A (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
CA002343094A CA2343094A1 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
SK510-2001A SK287491B6 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta-1 fusion proteins and their use |
IS5887A IS5887A (en) | 1998-10-16 | 2001-03-14 | Interferon-beta fusion proteins and their use |
IL142350A IL142350A (en) | 1998-10-16 | 2001-04-01 | Interferon-beta fusion proteins and pharmaceutical compositions containing the same |
US09/832,659 US6800735B2 (en) | 1998-10-16 | 2001-04-11 | Interferon-beta fusion proteins and uses |
NO20011861A NO20011861L (en) | 1998-10-16 | 2001-04-11 | Interferon <beta> fusion proteins and their use |
HK02103895.8A HK1042098B (en) | 1998-10-16 | 2002-05-24 | Interferon-beta fusion proteins and uses |
US10/868,673 US7527946B2 (en) | 1998-10-16 | 2004-06-15 | Interferon-beta-1a-immunoglobulin fusion proteins and uses |
CY20061101194T CY1105173T1 (en) | 1998-10-16 | 2006-08-24 | INTEPHONE FUSION PROTEINS -BETA AND USES |
US12/406,387 US20090286958A1 (en) | 1998-10-16 | 2009-03-18 | Interferon-beta fusion proteins and uses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10449198P | 1998-10-16 | 1998-10-16 | |
US60/104,491 | 1998-10-16 | ||
US12023799P | 1999-02-16 | 1999-02-16 | |
US60/120,237 | 1999-02-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/832,659 Continuation US6800735B2 (en) | 1998-10-16 | 2001-04-11 | Interferon-beta fusion proteins and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000023472A2 WO2000023472A2 (en) | 2000-04-27 |
WO2000023472A3 true WO2000023472A3 (en) | 2000-08-31 |
Family
ID=26801613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/024200 WO2000023472A2 (en) | 1998-10-16 | 1999-10-15 | Interferon-beta fusion proteins and uses |
Country Status (28)
Country | Link |
---|---|
US (3) | US6800735B2 (en) |
EP (1) | EP1121382B9 (en) |
JP (2) | JP4761621B2 (en) |
KR (1) | KR100767649B1 (en) |
CN (1) | CN100480266C (en) |
AT (1) | ATE327254T1 (en) |
AU (1) | AU766190B2 (en) |
BR (1) | BR9915548A (en) |
CA (1) | CA2343094A1 (en) |
CY (1) | CY1105173T1 (en) |
CZ (1) | CZ300762B6 (en) |
DE (1) | DE69931507T2 (en) |
DK (1) | DK1121382T3 (en) |
EA (1) | EA005005B1 (en) |
EE (1) | EE05111B1 (en) |
ES (1) | ES2265693T3 (en) |
HK (1) | HK1042098B (en) |
HU (1) | HUP0200414A2 (en) |
IL (2) | IL142350A0 (en) |
IS (1) | IS5887A (en) |
MX (1) | MXPA01003790A (en) |
NO (1) | NO20011861L (en) |
NZ (1) | NZ510559A (en) |
PL (1) | PL200586B1 (en) |
PT (1) | PT1121382E (en) |
SK (1) | SK287491B6 (en) |
TR (1) | TR200101087T2 (en) |
WO (1) | WO2000023472A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9169321B2 (en) | 2007-08-22 | 2015-10-27 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US9522945B2 (en) | 2012-04-19 | 2016-12-20 | Opko Biologics Ltd. | Long-acting oxyntomodulin variants and methods of producing same |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1039931T3 (en) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalent recombinant antibodies to treat HRV infections |
PT1121382E (en) * | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES |
PT1121156E (en) * | 1998-10-16 | 2006-05-31 | Biogen Idec Inc | CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US6697363B1 (en) | 2000-06-28 | 2004-02-24 | Alcatel Canada Inc. | Method and apparatus for longest matching prefix determination in a communication network |
AU2002212107A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | New multimeric interferon beta polypeptides |
AU2636602A (en) * | 2000-12-06 | 2002-06-18 | Applied Research Systems | Use of sarp-1 for the treatment and/or prevention of scleroderma |
CN1545553B (en) * | 2001-02-01 | 2011-09-21 | 弗·哈夫曼-拉罗切有限公司 | Method for producing recombinant trypsin |
DE60232434D1 (en) | 2001-02-27 | 2009-07-09 | Maxygen Aps | NEW INTERFERON-BETA-LIKE MOLECULES |
BR0208041A (en) * | 2001-03-15 | 2004-02-25 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
JP2005522192A (en) * | 2001-07-19 | 2005-07-28 | パーラン セラピューティクス, インコーポレイテッド | Multimeric proteins and methods of making and using multimeric proteins |
DK1471974T3 (en) * | 2002-02-06 | 2007-12-03 | Ares Trading Sa | Tumor necrosis factor combined with interferon in demyelinating diseases |
KR20050021502A (en) * | 2002-07-17 | 2005-03-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | THERAPIES FOR RENAL FAILURE USING INTERFERON-β |
WO2004020468A2 (en) * | 2002-08-28 | 2004-03-11 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
ES2343518T3 (en) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT. |
CN102038938A (en) * | 2002-09-27 | 2011-05-04 | 比奥根艾迪克Ma公司 | Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta |
US20040137581A1 (en) * | 2002-10-01 | 2004-07-15 | Xencor | Interferon variants with improved properties |
TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
JP2007503838A (en) | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス, インコーポレイティド | Method for producing fusion protein in milk of transgenic animals |
US20070212346A1 (en) | 2003-10-09 | 2007-09-13 | Tomoyuki Igawa | Highly Concentrated Stabilized Igm Solution |
PT1682583E (en) | 2003-11-13 | 2012-04-13 | Hanmi Holdings Co Ltd | Protein complex using immunoglobulin fragment and method for the preparation thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005074524A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
WO2005084303A2 (en) * | 2004-03-01 | 2005-09-15 | Enzon Pharmaceuticals, Inc. | Interferon-beta polymer conjugates |
US20050276785A1 (en) * | 2004-06-09 | 2005-12-15 | Schering Aktiengesellschaft | Treatment of cardiomyopathy and of endothelial dysfunction |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
JP5192823B2 (en) | 2005-01-12 | 2013-05-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Methods for delivering interferon-beta |
BRPI0616118A2 (en) | 2005-09-01 | 2011-06-07 | Ares Trading Sa | treatment of optic neuritis |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US7553941B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
WO2007110231A2 (en) * | 2006-03-28 | 2007-10-04 | Nautilus Biotech, S.A. | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EA020805B1 (en) | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Use of combination of cladribine and beta interferon for treating multiple sclerosis |
US8414897B1 (en) * | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
FR2907454B1 (en) * | 2006-10-18 | 2009-01-23 | Biomethodes Sa | IMPROVED VARIANTS OF INTERFERON BETA HUMAIN |
AU2008247815B2 (en) | 2007-05-02 | 2012-09-06 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2200634B1 (en) | 2007-09-21 | 2015-02-11 | The Regents of The University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
US20100203009A1 (en) * | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
WO2009053368A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
PE20110426A1 (en) | 2008-07-23 | 2011-07-01 | Ambrx Inc | MODIFIED BOVINE G-CSF POLYPEPTIDES |
MY151184A (en) | 2008-07-23 | 2014-04-30 | Hanmi Science Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
CN106995495A (en) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | Modified antibodies composition and its preparation and application |
RU2011138951A (en) * | 2009-02-23 | 2013-03-27 | Сайтомкс Терапьютикс, Инк. | PROTEINS AND WAYS OF THEIR APPLICATION |
AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
ES2555279T3 (en) * | 2010-02-12 | 2015-12-30 | Biogen Ma Inc. | Neuroprotection in demyelinating diseases |
WO2011106234A1 (en) | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
AR080993A1 (en) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
CA2838155C (en) * | 2011-06-07 | 2021-10-19 | Provasculon, Inc. | Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1 |
CN104080803B (en) * | 2011-10-01 | 2020-08-04 | 株式会社糖锁工学研究所 | Sugar chain-added polypeptide and pharmaceutical composition containing the same |
CN104203982B (en) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | Polypeptide construct and application thereof |
WO2014028502A1 (en) * | 2012-08-13 | 2014-02-20 | ImmunGene Inc. | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
MX363326B (en) | 2012-11-20 | 2019-03-20 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides. |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
KR102073748B1 (en) | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same |
MY171183A (en) | 2013-03-29 | 2019-09-30 | Glytech Inc | Polypeptide glycosylated with sialylated sugar chain |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
SG11201508923VA (en) | 2013-04-29 | 2015-11-27 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
CN104151420A (en) * | 2013-05-15 | 2014-11-19 | 复旦大学 | Long-acting interferon, preparation method therefor and applications thereof |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
AR096891A1 (en) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
KR20160098277A (en) | 2013-12-20 | 2016-08-18 | 에프. 호프만-라 로슈 아게 | Improved recombinant polypeptide production methods |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
KR102639037B1 (en) | 2014-10-29 | 2024-02-20 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | INTERFERON α2b VARIANTS |
KR102172937B1 (en) | 2015-06-19 | 2020-11-03 | 옵코 바이오로직스 리미티드 | Long-acting coagulation factor and its preparation method |
HRP20220304T1 (en) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
EP3356406A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
US11236141B2 (en) * | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
WO2021149945A1 (en) * | 2020-01-23 | 2021-07-29 | 주식회사 제넥신 | Fusion protein comprising pd-l1 protein and use thereof |
US20230129210A1 (en) * | 2020-04-03 | 2023-04-27 | The University Of North Carolina At Chapel Hill | Binding proteins useful against ace2-targeted viruses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
EP0225579A2 (en) * | 1985-12-02 | 1987-06-16 | G.D. Searle & Co. | Covalently linked polypeptide cell modulators |
WO1997024137A1 (en) * | 1995-12-28 | 1997-07-10 | Tanox Biosystems, Inc. | HYBRID WITH INTERFERON-α AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE |
US5783181A (en) * | 1994-07-29 | 1998-07-21 | Smithkline Beecham Corporation | Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3359030A (en) * | 1966-12-16 | 1967-12-19 | Newman George | Bumper guard assembly |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (en) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
JPS63152393A (en) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | Glycosyl derivative |
US4868802A (en) * | 1986-07-28 | 1989-09-19 | Kabushiki Kaisha Toshiba | Magnetooptic recording and erasing head which performs biasing, tracking and focusing |
US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
AU4660789A (en) | 1988-11-23 | 1990-06-12 | Genentech Inc. | Polypeptide derivatives |
DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5286637A (en) | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
JPH04218000A (en) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | Modified polypeptide |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
ES2199935T3 (en) | 1991-03-15 | 2004-03-01 | Amgen Inc. | PEGILATION OF POLYPEPTIDES. |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
AU2147192A (en) | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
WO1993012145A1 (en) | 1991-12-19 | 1993-06-24 | Baylor College Of Medicine | Pva or peg conjugates of peptides for epitope-specific immunosuppression |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5255519A (en) | 1992-08-14 | 1993-10-26 | Millennium Technologies, Inc. | Method and apparatus for increasing efficiency and productivity in a power generation cycle |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5874075A (en) | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5711944A (en) | 1993-11-10 | 1998-01-27 | Enzon, Inc. | Interferon polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
PT726778E (en) | 1994-02-08 | 2001-12-28 | Amgen Inc | ORAL ADMINISTRATION SYSTEM OF CHEMICALLY MODIFIED G-CSF PROTEINS |
US5545723A (en) | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
CA2206852A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
KR0154850B1 (en) * | 1995-10-09 | 1998-10-15 | 김광호 | Bicmos and its manufacturing method |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
JP2001508783A (en) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | PEGylation method |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
JP4078032B2 (en) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル,コーポレイション | Poly (ethylene glycol) derivatives with proximal reactive groups |
DE69920002T2 (en) | 1998-04-28 | 2005-09-22 | Applied Research Systems Ars Holding N.V. | CONJUGATES OF POLYOLE AND BETA-INTERFERON |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
PT1121382E (en) * | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES |
PT1121156E (en) * | 1998-10-16 | 2006-05-31 | Biogen Idec Inc | CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES |
JP2003527090A (en) | 1999-08-27 | 2003-09-16 | マキシゲン・エイピーエス | Novel interferon beta-like molecule |
WO2001046291A1 (en) | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
US20080033818A1 (en) | 2005-03-17 | 2008-02-07 | Inc2 Webcom Ltd. | Real time interactive response system and methods |
-
1999
- 1999-10-15 PT PT99956574T patent/PT1121382E/en unknown
- 1999-10-15 IL IL14235099A patent/IL142350A0/en active IP Right Grant
- 1999-10-15 EP EP99956574A patent/EP1121382B9/en not_active Expired - Lifetime
- 1999-10-15 SK SK510-2001A patent/SK287491B6/en not_active IP Right Cessation
- 1999-10-15 AT AT99956574T patent/ATE327254T1/en active
- 1999-10-15 MX MXPA01003790A patent/MXPA01003790A/en not_active IP Right Cessation
- 1999-10-15 HU HU0200414A patent/HUP0200414A2/en unknown
- 1999-10-15 DE DE69931507T patent/DE69931507T2/en not_active Expired - Lifetime
- 1999-10-15 DK DK99956574T patent/DK1121382T3/en active
- 1999-10-15 PL PL347932A patent/PL200586B1/en not_active IP Right Cessation
- 1999-10-15 TR TR2001/01087T patent/TR200101087T2/en unknown
- 1999-10-15 CA CA002343094A patent/CA2343094A1/en not_active Abandoned
- 1999-10-15 CN CNB998122130A patent/CN100480266C/en not_active Expired - Fee Related
- 1999-10-15 WO PCT/US1999/024200 patent/WO2000023472A2/en active IP Right Grant
- 1999-10-15 EE EEP200100223A patent/EE05111B1/en not_active IP Right Cessation
- 1999-10-15 AU AU13158/00A patent/AU766190B2/en not_active Ceased
- 1999-10-15 BR BR9915548-6A patent/BR9915548A/en not_active Application Discontinuation
- 1999-10-15 KR KR1020017004797A patent/KR100767649B1/en not_active IP Right Cessation
- 1999-10-15 EA EA200100447A patent/EA005005B1/en not_active IP Right Cessation
- 1999-10-15 JP JP2000577197A patent/JP4761621B2/en not_active Expired - Fee Related
- 1999-10-15 ES ES99956574T patent/ES2265693T3/en not_active Expired - Lifetime
- 1999-10-15 CZ CZ20011330A patent/CZ300762B6/en not_active IP Right Cessation
- 1999-10-15 NZ NZ510559A patent/NZ510559A/en not_active IP Right Cessation
-
2001
- 2001-03-14 IS IS5887A patent/IS5887A/en unknown
- 2001-04-01 IL IL142350A patent/IL142350A/en not_active IP Right Cessation
- 2001-04-11 NO NO20011861A patent/NO20011861L/en unknown
- 2001-04-11 US US09/832,659 patent/US6800735B2/en not_active Expired - Fee Related
-
2002
- 2002-05-24 HK HK02103895.8A patent/HK1042098B/en not_active IP Right Cessation
-
2004
- 2004-06-15 US US10/868,673 patent/US7527946B2/en not_active Expired - Fee Related
-
2006
- 2006-08-24 CY CY20061101194T patent/CY1105173T1/en unknown
-
2009
- 2009-03-18 US US12/406,387 patent/US20090286958A1/en not_active Abandoned
-
2010
- 2010-07-22 JP JP2010165349A patent/JP2010268810A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
EP0225579A2 (en) * | 1985-12-02 | 1987-06-16 | G.D. Searle & Co. | Covalently linked polypeptide cell modulators |
US5783181A (en) * | 1994-07-29 | 1998-07-21 | Smithkline Beecham Corporation | Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins |
WO1997024137A1 (en) * | 1995-12-28 | 1997-07-10 | Tanox Biosystems, Inc. | HYBRID WITH INTERFERON-α AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE |
US5908626A (en) * | 1995-12-28 | 1999-06-01 | Tanox, Inc. | Hybrid with interferon-β and an immunoglobulin Fc joined by a peptide linker |
Non-Patent Citations (2)
Title |
---|
ARDUINI RM. ET AL.: "Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.", PROTEIN SCI 1999 SEP;8(9):1867-77, XP000886314 * |
SANTILLAN G. E. ET AL.: "Conversion of Human Interferon-beta From A Secreted to a Phosphatidylinositol Anchored Protein by Fusion of a 17 Amino Acid Sequence to its Carboxyl Terminus", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 110, 1992, pages 181 - 191, XP000886368 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9169321B2 (en) | 2007-08-22 | 2015-10-27 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US9522945B2 (en) | 2012-04-19 | 2016-12-20 | Opko Biologics Ltd. | Long-acting oxyntomodulin variants and methods of producing same |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000023472A3 (en) | Interferon-beta fusion proteins and uses | |
AU688210B2 (en) | Recombinant obese (Ob) proteins | |
WO1999066054A3 (en) | Erythropoietin analog-human serum albumin fusion protein | |
EP1019028A4 (en) | $i(CHLAMYDIA) PROTEIN, GENE SEQUENCE AND USES THEREOF | |
AU7274898A (en) | Recombinant antibody-enzyme fusion proteins | |
AU6020598A (en) | Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi | |
WO2001025438A3 (en) | Ifn-alpha homologues | |
ZA200006309B (en) | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof. | |
AU7466198A (en) | Ucp3: an uncoupling protein homologue | |
EP1739090A3 (en) | Interferon-beta fusion proteins and uses | |
AU2511901A (en) | Basolateral sorting signal and inhibitors thereof | |
WO2000018909A3 (en) | NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM) | |
ZA963530B (en) | Recombinant obese (ob) proteins | |
AU3479699A (en) | A polypeptide comprising the amino acid of an n-terminal choline binding proteina truncate, vaccine derived therefrom and uses thereof | |
CA2197651A1 (en) | Or-1 on orphan receptor belonging to the nuclear receptor family | |
AU6301698A (en) | Anti-hiv peptides and proteins | |
AU2161699A (en) | Peptides and nucleic acids derived from (eisenia foetida) and the use thereof | |
WO2000029564A3 (en) | Human glycine transporter type 2 | |
AU1574699A (en) | Nucleic acids encoding (hev) structural proteins, (hev) structural proteins encoded thereby and uses thereof | |
IL135987A0 (en) | Lysozyme analogous proteins and peptides, processes for the preparation thereof and compositions and methods utilizing the same | |
AU8299598A (en) | Gmeb nucleic acids, proteins, and uses thereof | |
AU6981794A (en) | Protein which catalyses peptide refolding and uses thereof | |
AU1734800A (en) | (bartonella) proteins and uses thereof | |
AU2002301509A1 (en) | Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis | |
AU1534200A (en) | Novel major facilitator superfamily polypeptide, uses thereof and nucleic acids encoding same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99812213.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 13158 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13158/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 510559 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Country of ref document: CA Ref document number: 2343094 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 142350 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09832659 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-1330 Country of ref document: CZ Ref document number: 5102001 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01087 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2000 577197 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/003790 Country of ref document: MX Ref document number: 1020017004797 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999956574 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100447 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1999956574 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1330 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 13158/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999956574 Country of ref document: EP |